[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: All patients who underwent autologous SCT and have inclusion criteria will be enrolled and will receive the first dose of pastocovac from 3 months post-transplant. The second dose will receive at four weeks (\u00b17 days) interval of the first dose and the booster will receive at four weeks (\u00b17 days) interval of the second dose. The serologic responses will be assessed by measurement of SARS-CoV-2 specific IgG (anti-S1) before the first vaccine, before the second vaccine, four weeks after the second vaccine, and six months after the first vaccine.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionControl group: The control group includes healthy people who have received two doses of Pastococcal vaccine with the same formula and dose as the intervention group, and the antibody titer is measured before and after each dose of the vaccine", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "3 months post-transplant", "treatment_id": 2438, "treatment_name": "Pastocovac", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "healthy people", "treatment_id": 2438, "treatment_name": "Pastocovac", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: All patients who underwent autologous SCT and have inclusion criteria will be enrolled and will receive the first dose of pastocovac from 3 months post-transplant. The second dose will receive at four weeks (\u00b17 days) interval of the first dose and the booster will receive at four weeks (\u00b17 days) interval of the second dose. The serologic responses will be assessed by measurement of SARS-CoV-2 specific IgG (anti-S1) before the first vaccine, before the second vaccine, four weeks after the second vaccine, and six months after the first vaccine.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 515, "treatment_name": "Finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]